11:16 AM EDT, 06/23/2025 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Monday it has received two new international patents, raising its total global patent count to 50.

The company secured a patent in Australia for epilepsy treatment methods using its DehydraTECH technology. The Australian patent, which is part of Lexaria's family #24, is valid through 2044.

Lexaria also received a patent in Japan related to the sublingual delivery of nicotine, which is part of its patent family #20. The Japanese patent will be valid until 2043.

Shares of the company added 2% in recent trading activity.

Price: 0.98, Change: +0.02, Percent Change: +2.08